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Abstract
RMI1 (BLM-Associated Protein 75 or Blap75) is highly conserved from yeast to
human. Previous studies have shown that hRMI1 is required for BLM/TopoIIIα/RMI1
complex stability and function. However, in vivo functions of RMI1 remain elusive. To
address this question, I generated RMI1 knockout mice by homologous replacement
targeting. While RMI1+/- mice showed no obvious phenotype, deletion of both RMI1
alleles leads to early embryonic lethality before implantation. I then generated
RMI1/p53 double knockout mice. After ionizing radiation treatment at 4Gy, RMI1/p53
double-heterzygous mice showed shortened tumor latency and aggressive tumor
types when comparing with wild type, RMI1+/- and p53+/- control cohorts. My study
suggests a dual-functional role of RMI1 in early embryonic development and tumor
suppression.

vi

Table of Contents
Approval Page………………………………………………………………………………i
Title Page……………………………………………………………………………………ii
Dedication…………………………………………………………………………….…….iii
Acknowledgements………………………………………………………………………..iv
Abstract……………………………………………………………………………………..vi
Table of Contents…………………………………………………………………………vii
List of Illustrations…………………………………………………………………………xii
List of Tables……………………………………………………………….…….……….xiv

Chapter I. Introduction and Significance
Introduction of BLM…………………..…………………………..…………………………1
BLM mutants cause Bloom syndrome (BS) …………..………………….………….1
BLM belongs to RecQ DNA helicase family……………………………….…………2
Structure feature and biochemical activity of BLM protein………………….…...…6

vii

Biological function of BLM………………………………………...…………………10
The BTB complex……………………………………...…………………………………22
Components of BTB complex……………………………………….………………22
Introduction of Topo3α…………………………………………….…………………23
Introduction of Rmi1………………………………………………….………………25
Introduction of RMI2……………………………………………………….…………27
Activity of BTB complex…………………………..……………….…………………28
Mouse models of BTB complex proteins………………………………………………33
Mouse models of BLM……………………………………………………….……….33
Mouse model of Topo3α………………………………………….………….………34
Potential application of RMI1 mouse model……………………………….………34

Chapter II. RMI1 Is Required for Early Embryonic Development
Material and Methods…………………………………………………………...……….36
Identification and cloning of mRMI1 gene and full-length cDNA………………..36
Generation of mouse RMI1 knockout construct………………………………..…37
Identification of Rmi1 mouse ES cell clones………………………………………39

viii

Germline transmission…………………………………………………….………….40
Southern blot tests form ES cell genotyping………………………………….……41
PCR for mice and embryo genotyping……………………………………..….……41
Cell culture and Clonogenic survival assay…………………..…………….………43
Results………………………………………………………………………………..…….44
Generation of RMI1 Knockout Mouse Model……………………………….………44
Embryonic Lethality of RMI1-/- Mice……………………………………...………….47
P53-dependent Cell Proliferation in RMI1-depleted Cell………………….………50
p53-/- did not alleviate early embryonic lethality of RMI1-/- mice………………….………...51

Discussion……………………………………………………………………..….….…….54
RMI1 is essential for early embryonic development……………………..…………54
Functional relationship of Rmi1 and p53………………………………...….………56

Chapter III. RMI1 Heterozygosity Accelerates Induced-tumor Formation of
p53+/- Mice
Materials and Methods………………………………………………………….…..…….58
Ionizing radiation treatment and tumor analysis of animal model……..………….58
Genomic DNA extraction from fixed specimens…………………………..…..……59
ix

Preparation MEF cells………………………………………………………………..………..59
Immuno-staining of radiation-induced foci…………………………………………………..60

Results…………………………………………………………………………….………..61
Shortened half-life of radiation-induced foci in p53+/-RMI1+/- MEFs………………………61

Ionizing radiation fails to induce enhanced tumor formation in RMI1+/- mice…...62
Rmi1 heterozygosity accelerates IR-induced tumor formation of p53+/- mice…..67
LOH assays on RMI1 and p53 loci…………………………………………….….…72
Discussion……………………………………………………………………………...….78
Functional relationship between p53 and RMI1…………………………………………….78

Recessive haploinsufficiency of RMI1+/- mice…………………………………..…..79
Potential clinic application of RMI1 mouse model……………………...…….…….82

Chapter IV. Conclusion and Future Directions
Conclusion………………………………………………………………..…………….….84
Future Direction………………………………………………………………………..…..84
Study molecular modification of RMI1……………………………………..…..….…85
Study functional domains of RMI1………………………………………………...…86
Study potential protein partners of RMI1………………………………………....…87
x

Study RMI1 mutations/SNP in human cancers……………………………………87

Bibiliography…………………………………………………………………………….89

Appendix I Interactions of INO80 Complex Subunits
Introduction & Significance……………………………………………………………………….103
Classification of chromatin remodeling complexes……………………….…..……………103
Cellular functions of INO80 complex……………………………………………..………….109
Protein Components of INO80 Complex…………………………………..………………..112
Bimolecular fluorescence complementation assay……………………..………………….118
Goals of experiment……………………………………………………..…………………….118
Materials and Methods………………………………………………………..…………………..122
Cell Culture and cDNA Cloning/Transfection……………………………………………....122
Immunobloting and Green Fluorescent Signal Detection………………………….….…..123
Results……………………………………………………….……………………………………..124
Constructions and expressions of YFP-tagged INO80 subunits…………………….…...124
Fluorescence microscopy …………………….………………………………………..……127
Discussion…………………….…………………………………………………………..………..132

xi

Bibiliography ……………………………………………..………………………….…………….134

Appendix II Data Sheet of Irradiated Mice……………………………………..……….138

Vita………………………………..……………………………………………………….142

xii

List of Illustrations
Chapter I, II, III & IV
Figure 1. Schematic of RecQ helicase family members from various organisms….3
Figure 2. Protein structure and map of interaction regions of BLM. ……….………..7
Figure 3. BLM prevents crossovers in DSB repair. ……….……….….….………….20
Figure 4. Model of BTB complex ‘dissolution’ activity. ……….……….…..…………31
Figure 5. Replacement targeting of the RIM1 locus. ……….……….………..……...45
Figure 6. Clonogenic survival assay of Rmi1 knockdown in HCT116 cells. ……....52
Figure 7. Foci staining 6, 24, and48h after IR (1.5gy)…..…………………………….63
Figure 8. Accelerated and enhanced IR-induced tumorigenesis in Rmi1+/- p53+/mice………………………………………………………………..………………………..70
Figure 9. Aggressive tumors derived from the RMI1+/- p53+/- mice. …………….…..74
Figure 10. LOH assay of RMI1 and p53 loci. ……….…...……….……….…………..76

Appendix I
Figure 1. Known domains and interactions of Ino80 protein. ……..….……….……115
xiii

Figure 2. Principle of BiFC assay. ……….……….……….………………….……….120
Figure 3. Western blots for YFP fragments tagged INO80 complex subunits. …..125
Figure 4. Fluorescent microscopy of BiFC assay ……….…...……….…….……….128

xiv

List of Tables
Chapter I, II, III & IV
Table 1. Summary of embryonic genotypes. ……….……….………...….……..…….48
Table 2. Summary of foci-negative MEF populations 24 or 48 hours after IR……...65
Table 3. Summary of induced-tumors from Rmi1+/- p53+/- and control groups. ....…68

Appendix I
Table 1. List of covalent histone modifications. ……….……...…….…………..……105
Table 2. List of ATP-dependent chromatin remodeling complexes. ………..…..…107
Table 3. Subunits of budding yeast and human INO80 complexes. ……...……….113
Table 4. summary of protein-protein interactions among INO80 complex subunits
identified by BiFC assay…………………………………………………..…………….130

xv

Chapter I

Introduction & Significance

1.0 Introduction of BLM

1.1 BLM mutants cause Bloom syndrome (BS)

Bloom syndrome (BS) is a rare autosomal recessive disorder. Since first described
in 1954, more than 170 cases of BS patients have been reported. One of the major
clinical features of Bloom syndrome is the high frequency of cancers at early ages.
Moreover, in contrast to other cancer-prone disorders such as Fanconi anemia (FA)
or Ataxia telangiectasia (AT) (1, 2), BS patients are exposed to a much broader
spectrum of malignancies, which includes almost all types of cancers affecting the
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general population. Additional features of this syndrome include dwarfism, sun light
sensitivity, male infertility, and immunodeficiency (3).

BS is caused by defects in the BLM (Bloom Syndrome Mutated) gene. Until recently,
at least 64 different BLM mutations derived from BS patients have been identified (4,
5). Most mutations are nonsense or frame-shift ones that cause premature proteintranslation termination. Missense contributes up to 16% of total BS-associated
mutations (4). Among all known mutations, BLMAsh, first identified from Ashkenazi
Jews population which bears the highest risk of BS, corresponds to a 6-bp deletion
and a 7-bp insertion at position 2207 (6). Interestingly, unlike most other recessive
disorders, the BLMAsh allele is reported to be haploinsufficient. Carriers of one copy
BLMAsh allele are exposed to an increased risk of colorectal cancer (7, 8).

1.2 BLM belongs to RecQ DNA helicase family

BLM belongs to RecQ DNA helicase family (Figure 1.), a member of SF2 helicase
superfamily (9). RecQ helicases are highly conserved from bacteria to humans.
Helicases from this family contain a conserved helicase domain consisted of seven
characteristic sequence motifs (10). In addition, most RecQ helicases present other
conserved domains, including the RQC (RecQ C-terminal) and HRDC (helicase and
RNase D C-terminal) domains (11, 12).
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The number of RecQ helicases in different species varies. It seems that this number
is associated with organism complexity. Whereas Escherichia coli and
Saccharomyces cerevisiae only contain a single RecQ helicase (RecQ and Sgs1,
respectively), human cell expresses at least five of the RecQ family members:
RECQL1, RECQL4, RECQL5, WRN, and BLM (9).

Besides BLM, mutations of some of the other human RecQ helicases also lead to
genetic disorders. For example, mutations in the RECQL4 and WRN gene cause
Rothmund-Thomson syndrome and Werner syndrome, respectively (13, 14). Both
syndromes are manifested by predisposition of cancers. However, unlike BS
patients who have increased susceptibility to a wide spectrum of cancers, patients of
Rothmund-Thomson or Werner syndrome are prone to certain types of cancers,
such as osteosarcoma and thyroid cancers, respectively.

Previous studies have shown that all RecQ helicases possess several common
enzymatic activities, such as: 1) DNA- and Mg2+-dependent ATPase activity; 2), 3’ to
5’ DNA helicase activity (with the exception of RECQL4 (15)); 3) complementary
single strand DNA annealing;, 4) Branch migration of Holiday Junctions; 5)
replication fork regression. However, although human RecQ helicases, especially
BLM and WRN, have similar biochemical activities, and their defective cells both
display chromosomal integrity related phenotypes, their functions are mostly nonredundant (9).
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1.3 Structure feature and biochemical activity of BLM protein

The hBLM protein comprises 1417 amino acids. As previously described in this
chapter, BLM contains several conserved domains common in RecQ helicase
family, including a central SF2 helicase domain of repeat motifs, a RQC (RecQ Cterminal) and a HRDC helicase and RNase D C-terminal) domain (Figure 2.).
Among them, the helicase domain possesses both DNA helicase and ATPase
activity. The RQC domain, on the other hand, forms a zinc-binding scaffold, which is
required for this protein’s structural stability. Moreover, the winged-helix (WH) sub
domain of RQC domain is response for DNA binding (16). The third conserved
domain of BLM, the HRDC domain is indispensable for the efficient binding and
unwinding activities of double Holliday junctions (17). Taking together, all of three
domains are important in terms of proper BLM activity, as disease-causing mutations
in all three domains have been found in BS patients.

Consistent with activities of its RecQ helicase homologs, BLM is able to recognize
and unwind a wide variety of DNA substrates. These substrates include, but not limit
to DNA structures depicting replication forks (forked duplex), replication obstacles
(G-quadruplex), and recombination intermediates (Holliday junctions, D-loops) (1820). The capability of unwinding such DNA substrates suggests that BLM is likely
involved in cellular events of DNA metabolism, such as DNA replication, repair and
telomere
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maintenance. Interestingly, blunt-ended dsDNA, which represents normal DNA
structure, is not a substrate of BLM (18). Moreover, BLM is proposed to have a
‘reversed’ helicase activity by catalyzing complementary ssDNA annealing (10).

The hallmark feature of cells derived from BS patients is the elevated Sister
Chromatin Exchange (SCE) level, which still serves as the only objective criterion for
BS diagnosis (5). The elevated SCE level could also been observed from mouse
BLM-/- cells, and BLM-/- DT40 cells(21-23). SCE is the process that two sister
chromatids physically exchange duplex strands by breaking and rejoining DNA
chains (24). Although this process does not involve alternation of genetic
information, and is generally considered to be conservative and error-free, elevated
SCE level may be associated with increased risk of cancers (25). Because
reciprocal interchange of SCE is carried by homologous recombination (HR)
pathway, the SCE therefore represents, at least indirectly, the cellular HR activity.
The fact that the SCE level of BS cells is approximately 10-fold higher than wild type
cells indicates BLM function in preventing chromatid exchanges (21). Along with
elevated SCE level, BLM-defective cells displayed increased frequency of gene
targeting efficiency, loss of heterozygosity (LOH) rate, accumulated chromosome
aberrations and IR-sensitivities (26-29). Conclusively, BLM is believed to play an
important role in maintaining genomic stability and chromosomal integrity.

9

1.4 Biological function of BLM

For the last two decades or so, functions of BLM have been extensively investigated.
Although the exact mechanisms remain obscure, it is widely accepted that BLM
involves multiple cellular processes related to DNA metabolism. These processes
include DNA replication in S phase, chromatin separation in M phase, DNA-damage
response checkpoint regulation and DNA repair.

1.4.1 BLM function in DNA replication

1.4.1.1 Importance of DNA replication
DNA replication is the fundamental process for biological inheritance. The efficiency
and fidelity of replication is critical for all eukaryotes. During replication, the
replicated chromosome is unwounded by DNA helicases, which leaves two single
stranded DNA branching open and complemented by newly synthesized DNA. This
particular Y-shaped DNA structure is termed replication fork. In normal situations,
DNA replication starts with origins when two DNA strands are separated in order to
form two replication forks proceeding in opposite directions, and ends when all forks
meet and terminate (30). However, replication forks could be stalled by various
reasons, such as encountering DNA breaks and defects (31-33). If not rescued,
10

failed replication forks would lead to interrupted replication process, stalled cell cycle
or even cell death.

1.4.1.2 BLM helps to restart stalled replication forks during S phase.

The cellular expression of BLM protein is tightly regulated in cell type- and tissuespecific manners. In general, BLM expresses in all actively dividing cells with active
cell proliferation. Therefore, testis, ovary, thymus and spleen are the organs that
have the highest levels of BLM expression (23). Surprisingly, despite its function in
maintaining genomic stability, most tumor cells express BLM at higher levels,
presumably in keeping with the faster cell proliferation (34).

BLM expression is also temporally regulated as a function of the cell cycle (35-37).
The BLM protein is abundant in both S and G2, but absent in the G1 phases. It is
believed that proteolytic degradation after M phase leads to the undetectable BLM
protein level in G1 phase (37), although direct evidence remains to be uncovered.

Several evidences suggest an association between BLM and DNA replication
process. First, cell cycle-specific expression pattern of BLM is consistent with
cellular process of DNA replication, as the peak of BLM protein level occurs since S
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phase. Second, during S phase, the nuclear location of BLM foci overlaps with
PCNA in damage-induced sites, an indication of BLM’s involvement in maintaining
proper DNA replication (27). However, BLM has not been found to be a constitutive
component of the replisome and does not directly involve in DNA replication
process. Studies of BLM orthologue in yeast suggest that unstrained activity of Sgs1
is toxic for cells (38-40). In conclusion, BLM is not required for normal replication
process.

Moreover, under normal conditions, BLM is localized in PML nuclear bodies (PMLNBs) (41). PML-NB is named after PML gene, which is originally identified as the
site of translocations in acute promyelocytic leukaemia (42). Although direct
interaction between BLM and PML is yet to be confirmed, the region targeting BLM
to PML-NB localization had been mapped, as BLMΔ133-137 mutation failed to colocalize with PML-NBs (43). BLM localizes in PML-NBs together with some of its
protein partners and other proteins involved in DNA metabolism. However, the
function of this co-localization is still debatable. The co-localization of BLM and PMLNB is never complete (44, 45). Nevertheless, the localization of BLM to PML-NBs is
not vital to BLM function. Although in PML-deficient cells, BLM is unable to
concentrate into foci but spread uniformly in nucleoplasm (44), expression of mutant
BLM with disturbed PML-NB colocalization capability corrects high SCE level in BS
cells (45). It is very likely that PML-NBs serve as temporary storage sites for BLM
proteins, where BLM can be shuttled to and from PML-NBs in a timely manner. This
view is well supported by independent studies. For example, in response to DNA
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hydroxyurea induced replication stress, BLM leaves PML-NBs and re-localizes to
stalled replication forks (46).

Although the translocation of BLM from storage sites to stalled replication forks has
been an acceptable dogma and BLM is also known to unwind G-quadruplexes as
well as other DNA secondary structures that may present as roadblocks during
replication, the mechanism of BLM in ensuring DNA replication remains elusive.
Several hypothesizes have been raised. Although different in details, they all
propose BLM’s function in restarting stalled replication forks.

One of the possible consequences of failing to restore collapsed replication forks is
DSBs at damage sites, which may lead to inappropriate strand exchanges by the HR
repair machinery (47, 48). It is believed that BLM is required for stabilization and
subsequent restart of replication forks blocked by DNA lesions (49). Heller et al.
proposed that BLM may help to obtain a configuration of nascent strands, a ratelimiting step in replication restart (50, 51). Another possible mechanism suggests
that BLM promotes fork regression to ‘chicken feet’ formation at damage site, thus
allows the replication machinery to use the nascent lagging strand as a template to
bypass DNA lesion (52).

In summary, the presence of BLM in S phase helps to restart stalled replication
forks, which prevent possible chromosome rearrangements promoted by collapsed
replication forks, as one of its function in maintaining chromosomal integrity.
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1.4.2 BLM in S phase checkpoint

1.4.2.1 Checkpoint pathway ensures proper cellular progresses.

Cells are most vulnerable during S phase in terms of generating replicationassociated mutants. Any error in the replicative process, if not properly treated, may
lead to more dangerous forms of lesions that could affect genomic integrity, or even
cell viability (53). In response to replication stresses, the S phase checkpoint
pathway acts to suppress the firing of replication origins before DNA lesions are
removed. Thus, the S phase checkpoint mechanism is important for both replication
fidelity and cell survival (54).

1.4.2.2 BLM in S phase checkpoint

Recent studies suggest that during S phase and in addition to its role in restarting
stalled replication forks, BLM may also be involved in S phase checkpoint pathway
(55). BLM is known to interact with multiple proteins participating in S phase
checkpoint pathways. BLM interacts with BRCA1 and was also identified as a
component of BASC complex, a multi enzyme complex containing BRCA1 and
several other proteins such as MLH1, MSH2, MSH6, RFC, and ATM. This
interaction seems to be DNA damage-associated, because the co-localization of
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BLM and BRCA1 foci increases following HU treatment (56). The functional
significance of this complex, however, remains to be demonstrated.

BLM has functional and physical interactions with other checkpoint/DNA damage
signaling proteins such as the MRN complex, p53, γ-H2AX, ATR and ATM (46, 57,
58). During S phase, followed DNA damage agent introduction, BLM is rapidly
recruited onto damaged sites and co-localizes with γ-H2AX (59) This translocation
may allow BLM interacting with ATR, Chk1 and 53BP1, and facilitating accumulation
of them and other checkpoint proteins onto the damaged sites (60). In the absence
of BLM, this recruitment of multiple proteins to damage sites is either absent or
delayed, indicating a BLM-associated S phase checkpoint pathway (57).
Interestingly and surprisingly, BLM’s role in this process may be non-catalytic, since
the helicase-defective mutant of BLM is able to support the recruitment of the above
checkpoint factors to the damage-induced foci (57),

1.4.3 BLM in telomere maintaining

In normal condition, telomeres are regulated by a special reverse transcriptase
termed telomerase (61). Some human cell lines and primary tumor cells, however,
maintain their telemeres using an alternative mechanism named alternative
lengthening of telomeres (ALT) (62). TRF2, which is one of the key components of
the telomere complex, is involved in this recombination-dependent telomere
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maintenance (63). It forms heterdimer with TRF1, and both proteins are thought to
be involved in regulating telomeric length (64, 65).

The physical interaction between BLM and TRF2 has been identified both in vitro
and in vivo (66). Interestingly, the co-localization of BLM and TRF2 was only
observed in ALT cells but not telomerase-proficient cells (66). Overexpressing BLM
results in ALT cell-specific increases in telomeric DNA (67), which suggests that
BLM promotes recombination-dependent amplification of telomeres in ALT cells.

1.4.4 BLM in M phase

BLM seems to be indispensable for faithful sister chromatids separation during M
phase (68). Defective separation processes were observed from yeast ΔSgs1 and
Drosophila BLM-/- cells (69). The same phenotype was also shown from BS cells.
Comparing with cells ectopically expressing BLM protein, BLM-defective cells have
higher frequency of anaphase bridges and lagging chromatins. Nevertheless, BLM
localizes to anaphase bridges with its protein partners (70). It is suggested that BLM
ensures chromatid separation by facilitating complete sister chromatid decatenation
in anaphase.
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1.4.5 BLM in HR

1.4.5.1 General introduction of HR

DNA double strand break (DSB) is one of the most severe DNA damages to cells
(71). Improper repair of DSB could result in accumulated chromosomal aberraions,
abnormal rearrangement of the genome, arrested cell cycle or even cell death (72).
In mammalian cells, two distinct pathways, NHEJ and HR, are the two major repair
mechanisms in response to DSBs (73). The NHEJ directly ligates, with minimum
processing, two exposed chromosome ends together without the need of
homologous DNA template (74). The HR, on the other hand, utilizes a homologous
sequence as template to replicate the damaged part (75). Thus, it is understandable
that cells exhibit dominating HR activity in S and G2 but not G1 phases. Since in S
and G2 phases, sister chromatids are readily available as homologous templates for
HR.

Following DSB formation, the exposed DNA ends are first resected by DNA
exonuclease to release 3’ single-strand overhangs. Next, these overhangs
form a "presynaptic filament" with Rad51 and its paralogs, which leads to the
invasion of a homologous region. During the invasion process, a ‘D-loop’
intermediate DNA structure is formed. After the strand invasion, DNA synthesis
occurs on the invading strand to restore the broken chromosome. Another DNA
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intermediate, Holliday junctions (HJs), are created during DNA synthesis. The HJs
are proposed to be solved by DNA helicases, in either crossover or non-crossover
manners (76, 77).

1.4.5.2 BLM function in HR

One of BS cell’s characterized features is elevated SCE level, which indicates
increased chromatid exchange activity in the absence of BLM protein. As discussed
previously, the increased SCE level represents elevated HR activity in BS cells.
Previous studies suggest that BLM prevents this activity in two ways.
Simultaneously, it inhibits entry of cross over-causing HR and, during HR, it resolves
DNA intermediates in a non-crossover manner (78, 79) (Figure 4.).

BLM displays anti-HR activity. It is widely recognized that the initial step of HR is the
invasion of Rad51-coated ssDNA to homologous region (80). BLM can actively
disrupt Rad51-ssDNA filaments. This disruption inhibits the invasion of homologous
region and formation of ‘D-loop’ DNA intermediate (81). Since the Rad51 recruitment
and strand invasion are the initial steps of HR, BLM could alter the repair
mechanism from HR to non-cross over causing ones such as single strand
annealing (SSA) or synthesis-dependent strand annealing (SDSA) (81).
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On the other hand, BLM also plays a critical role in resolving DHJ intermediate.
BLM, in coordination with its partner proteins Topo3α and Rmi1, forms BTB complex
(82). During the last steps of HR, this BLM-containing complex is capable of
promoting HJ migration and dissociation in a non-crossover manner (20, 83). The
components, structure and activity of BTB complex will be discussed in coming
sections.
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2.0 The BTB complex

2.1 Components of BTB complex

Three BLM-associated complexes, termed BLM complex I, II and III, have been
isolated by Meeti et al. using biochemical purifications (84). Proteins from these
complexes were identified by mass spectrometry. Most proteins identified have
known physical interactions with BLM, including 5 Fanconi anemia (FA) proteins.
Similar to BLM, defective FA proteins lead to genomic instability and show clinical
features of cancer disposition (85). The fact that FA proteins and BLM co-exist as
complexes may indicate a connection between the two pathways in maintaining
genomic integrity (78).

Interestingly, only two proteins are consistently presented in all three BLMassociated complexes. They are the DNA topoisomerase Topo3α and a newly
identified novel protein Rmi1 (RecQ-mediated genomic instability 1, also named
Blap75) (82). These two proteins, together with BLM, form a core complex termed
BTB complex, referring to BLM, Topo3α, and Rmi1 (Blap75). The formation of the
BTB complex is conserved from yeast to human (86, 87). Recently, the forth
member of this complex, Rmi2 has been independently identified by two groups (88,
89). However, unlike all three other components of BTB complex, it only expresses
in plants and vertebrates.
22

2.2 Introduction of Topo3α

2.2.1 Topo3α belong to type IA DNA topoisomerase subfamily

DNA topoisomerases are essential for almost all DNA metabolic processes,
including compaction, replication, transcription, strand separation and
recombination. All of these processes require exposing of accessible DNA helix (90,
91). DNA topological structures, which are generated during DNA metabolism, may
be roadblocks in these processes. There are three main types of topology:
supercoiling, knotting and catenation. DNA topoisomerases are able to break and
reseal DNA backbones to facilitate topological changes and wind/unwind DNA.
These enzymes could be structurally and mechanistically different. Based on the
number of strands cut in one round of action, the majority of DNA topoisomerases
can be separated into two families: type I and type II (90). Whereas the type I
topoisomerase resolve topological structures by breaking and rejoining one strand of
DNA helix, the type II topoisomerases act on both strands. The third DNA
topoisomerase family, TopoV, is consisted of only one member (92).

Based on the polarity of strand cleavage, Type I topoisomerase family can be further
divided into two subfamilies: IA and IB (93). The topoisomerases from type IA
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subfamily are monomeric and able to unwind DNA substrates by breaking and
sealing one DNA strand (94). The DNA helicase in the BTB complex, Topo3α,
belongs to type IA topoisomerase subfamily, which is conserved in all organisms.

2.2.2 Cellular function of Topo3α

Function of Topo3α remains poorly understood. Yeast top3 mutant strain shows
phenotypes of hyper-recombination, slow growth, defective S phase checkpoint and
abnormal sporulation (95-97). Interestingly, the phenotypes of top3 loss-of-function
mutation can be suppressed by mutations in HR genes, or additional deletion of
Sgs1, the only RecQ helicase in yeast (98-100), indicating a genetic interaction
between Topo3α and Sgs1.

Although Topo3α is able to bind and unwind DNA substrates, its relaxation activity is
weak. Thus it is believed that Topo3α is not involved in the maintenance of DNA
supercoiling homeostasis (101). However, it is required for proliferation and telomere
stability in ALT (Alternative Lengthening of Telomeres) cells where Topo3α
physically interacts with TRF2 (102). Knockdown Topo3α by siRNA induces TRF2
depletion, inhibited growth, anaphase bridge formation, and telomere dysfunction in
such cells. Thus it is proposed that Topo3α/BLM/TRF2 complex may be in response
of maintaining telomere stability in ALT cells.
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Topo3α function is also associated with BLM and BTB complex. The activity of this
complex as well as Topo3α’s role will be discussed in section 2.5 of this chapter.

2.3 Introduction of Rmi1

2.3.1 Protein structures of RMI1

The hRmi1 harbors 625 amino acid residues and has a molecular weight of 75kDa
(82). Examination of Rmi1 protein reveals three conserved domains: a DUF1767
(Domain of Unknown Function 1767, named by Genebank) and two OB-fold
(Oligonucleotide/oligosaccharide-binding ) domains (OB1 and OB2, respectively)
(89). The exact function of DUF1767 domain remains unknown. Meanwhile, the two
OB-fold domains share sequential similarities to OB-fold domains found in RecG and
RPA1-C, respectively. Although OB-fold domain is generally considered as a DNA
binding domain, the two domains in RMI1 lack several conserved residues that are
important for DNA binding. Therefore it is predicted that Rmi1 has weak or no DNA
binding activity. However, in vitro assays conducted by several groups lead to
opposite results and the DNA binding activity of Rmi1 remains controversial (89,
103). It is still possible, however, that Rmi1 may bind DNA substrates only in the
context of BTB complex. On the other hand, Rmi1 OB-fold domains may participate
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in specific protein-protein interactions. A recent study has shown that OB1 and OB2
domains of Rmi1 are response for interactions with Topo3α and Rmi2, respectively
(89). A point mutation in OB1 domain disrupts Rmi1-Topo3α interaction, and
abolishes biochemical activity of BTB complex.

2.3.2 Function of RMI1

Previous studies from our lab and others have shown that Rmi1 is required for BTB
complex stability and activity (82, 89). Rmi1 is required for normal cell proliferation.
Rmi1 knockdown cells exhibit reduced cell density and drastic decrease in colony
survival assay. Surprisingly, these cells do not display any sign of specific cell cycle
arrest or apoptosis. One plausible explanation is that Rmi1 depletion leads to
reduced proliferation. Rmi1 is also required for genomic stability. The Rmi1
knockdown cells display elevated SCE level, a characteristic feature of BS cells. The
SCE level of Rmi1 knockdown cells is comparable to that of BLM knockdown cells
as observed in our laboratory.

Further investigations have revealed that Rmi1 activity is associated with its partners
in the BTB complex. First, Rmi1 has directly physical interactions with all three other
components of BTB complex. These interactions are essential for this complex’s
stability. Nevertheless, Rmi1 is also required for normal BLM function. BLM is known
to be hyperphosphorylated on Thy-99 and Thy122 in response to mitosis blockage
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induced by chemicals or IR, which is ATM-dependent (28, 37). Mutations on either
site fail to correct radiosensitivity in BS cell. BLM is also able to translocate to DNA
damaged sites or stalled replication forks upon induced genotoxic stress. This
translocation is known to be essential for checkpoint activation and damage repair
processes. Both activities of BLM are severely impaired in RMI1 depleting cells (82),
indicating RMI1 is indispensable for BLM function.

2.4 Introduction of RMI2

Recently, the forth member of BTB complex, Rmi2, has been identified (88, 89).
However, its presence in the BTB complex is not evolutionary conserved. In fact,
Rmi2 is only expressed in certain vertebrates and plants. Rmi2 directly binds to
Rmi1 with its OB-fold Domain but does not have physical interaction with either
Topo3α or BLM. It is required for BTB complex stability. Depletion of Rmi2 protein by
siRNA knockdown leads to elevated SCE level, reduced protein level of Topo3α,
Rmi1 and BLM. However, its capacity of maintaining BTB complex stability is
depending on Rmi1. Nevertheless, in vitro experiments showed that the Rmi1/Rmi2
complex, but not Rmi2 alone could facilitate Topo3α/BLM resolution activity.

27

2.5 Activity of BTB complex

2.5.1 RMI1 and Topo3α are required for BTB complex stability

The structure and function of the BTB complex appear to be evolutionarily
conserved among eukaryotes. Physical interactions between Rmi1 and Topo3α/BLM
are required for BTB complex stability (89). Raynard et al. have shown that the Nterminal region of Rmi1 is required for both Topo3α and BLM interactions (104).
Interestingly, Rmi1 and Topo3α’s stabilities are highly depended on each other(89).
Knockdown of either of them could lead to drastic decreased protein level of the
other one. In comparison, BLM protein level is less affected by depletion of either
protein, and knockdown of BLM does not diminish Rmi1 and Topo3α protein levels,
as protein levels of both Rmi1 and Topo3α remain unaffected in BLM knockdown
cells.

2.5.2 Biochemical activity of BTB complex

Current model suggests that BTB complex has ‘dissolution’ activity in processing
DSB repair intermediates during the last steps of HR (105). Followed by replication
and DNA end rejoining in HR, the invading strand is trapped in between two
homologous strands from sister chromatin, and partially annealed to one of them.
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This DNA intermediate structure is termed double Holliday junction (DHJ). If not
resolved, DHJ could lead to chromosome break during mitosis (106). Several DNA
helicases and their complexes are proposed to having activities in resolving this
intermediate. All of them are able to physically break and rejoin DNA strand(s).
During this process, DNA ends may rejoin to their original strands (non-crossover) or
be exchanged to their sister chromatins (crossover). A typical resolving helicase
randomly opens nicks on strand(s), which give rise to equal possibilities of both
crossover and non-crossover products (107). However, as other candidates may
lead to strand exchange between sister chromatins, the BTB complex is specialized
in unwinding DHJ using an alternative process termed dissolution, which completely
prevents strand exchange between chromatins (79, 103, 108, 109).

Both BLM’s DNA helicase and Topo3α’s DNA Topoisomerase activities are needed
during this process. Moreover, these two proteins are non-redundant in DHJ
dissolution, as other helicases/Topoisomerases are unable to substitute their
functions (103). Although the molecular basis behind this dissolution activity is still
poorly understood, a working-model of BTB complex activity has been proposed
(107) (Figure 4.). Under this model, first, BLM is capable of promoting migration of
two HJs together to form another intermediate structure referred as hemicatenine.
Next, Topo3α acts on the hemicatenated DNA substrates to unwind homologous
chromatins and complete HR in a non-crossover manner.
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Although Rmi1 does not have any known enzyme activity, proper BTB complex
activity requires the presence of the Rmi1 protein. The presence of Rmi1 could
facilitate HJ unwinding activity of BLM/Topo3α in vitro as the HJ unwinding activity of
BLM/Topo3α combination could be enhanced by as much as 25-fold in the presence
of Rmi1 (103). Moreover, under salt conditions mimicking physiological environment,
the DHJ dissolution activity of BLM/Topo3α is completely dependent on Rmi1
presence (110). Interestingly, the Rmi1/Topo3α interaction is also required for BTB
complex activity. The N-terminal fragment of Rmi1 is able to efficiently promote
BLM/Topo3α dissolution activity. Moreover, Rmi1 K166A, a point mutation which
ablates its binding with Topo3α, is unable to promote that activity under the same
condition (110). It is very likely that Rmi1 has a regulative role in BTB complex
function, where it secures Topo3α onto DNA substrates.

Nevertheless, the activity of this complex is depended on ATP hydrolysis. The only
protein in BTB complex with known ATPase activity is BLM. This suggests that
other than its helicase activity, BLM’s ATPase activity is also required for this
complex’s ‘dissolution’ function (109). In concordance with this, BLM variants with
defective ATPase motifs are devoid of HJ unwinding activity.
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3.0 Mouse models of BTB complex proteins

3.1 Mouse models of BLM

At least three groups have independently generated BLM mouse models. The first
two models generated by Chester et al. and Goss et al. both followed similar
knockout strategies, from which a part of BLM gene was replaced with a selective
marker cassette (23, 111). Both strategies led to lethality of BLM-/- embryo. The
BLM-/- model from Chester et al. displayed reduced cell number, increased apoptosis
rate and delayed development during early embryonic stages. These embryos
eventually die at 13.5 days post coitum (23). The lethality of the other BLM model
has not been reported in detail. BLM+/- mice from this group, on the other hand,
showed increased cancer susceptibility when injected with murine leukemia virus or
crossed with APC mice (111). However, BLM heterozygosity alone does not seem to
promote tumor development.

The third BLM mouse model from Alan Bradley’s lab was generated by a different
strategy, from which the coding sequence of BLM cDNA is disrupted by exon
replication (26). Surprisingly, homozygosity of this mutation did not cause embryonic
lethality. A possible explanation is that although from its BLM-/- strain, no protein
product was detected by anti-BLM antibodies, it is widely believed that unlike the
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other two BLM strains with complete absence of BLM gene product, this mutation
may retain some of BLM’s function. This mouse model partially resembled clinic
features of BS syndrome, such as cancer-prone phenotype and elevated SCE level.

3.2 Mouse model of Topo3α

Topo3α-/- leads to pre-implantation embryonic lethality. Culturing of Topo3α-/blastocysts first showed proliferation defects after hatching, and the growth was
completely stopped thereafter (112). Despite the severe phenotype of Topo3α-/mice, Topo3α+/- mice appeared normally.

3.3 Potential application of RMI1 mouse model

We decided to generate a mouse genetic model of RMI1 for the following reasons:
First, an animal model of RMI1 could help us better explain the molecular functions
of RMI1. Previous advances of RMI1 were mainly accumulated through in vitro
biochemical assays or experiments conducted in Rmi1 knockdown cell lines. These
studies, however, could be influenced by selection of artificial environments or
residual effects of remaining Rmi1 protein, respectively. Thus, a complete deletion of
RMI1 from the genome at the animal level could provide a bias-free system to study
the in vivo impact of Rmi1.
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Second, RMI1 mouse model may help us to reveal its physiological function. While
BLM is known to be associated with BS, Topo3α and Rmi1 have not been linked to
any specific human disorder yet. Thus, the animal models could be one way to study
their physiological function. Because of Rmi1’s close relationship with BLM, if
existing, disorders caused by defective RMI1 in either human or mice could exhibit
cancer-prone phenotypes as well. Thus, our RMI1 mouse model could serve as a
potential animal model in cancer biology.
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Chapter II

RMI1 Is Required for Early Embryonic Development

1.0

Materials and Methods

1.1

Identification and cloning of mRMI1 gene and full-length cDNA

The mRMI1 gene was identified by searching homologous sequence in NCBI
database against full-length hRmi1 cDNA. A full-length mRmi1 cDNA clone
(BC037694) was obtained from MGC (Mammalian Gene Collection) and used as a
probe to screen the RPCI-22 library, a mouse genomic DNA BAC library. To
construct this library, DNA extracted from female 129S6/SvEvTac (Taconic) mouse
spleen was isolated and partially digested with a combination of EcoRI and EcoRI
Methylase before cloning into the pBACe3.6 vector between the EcoRI sites. This
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library gridded onto 22x22cm nylon high-density filters for screening was purchased
from commercial sources. Three clones hybridized with p32-labled mRmi1 cDNA
probes, 444B20, 269A5 and 444P22, were identified from my screening. Later, all
three BAC clones were shown to contain whole mRmi1 gene sequence. In our
study, we used clone 444B20 as the DNA template for vector construction.

1.2 Generation of mouse RMI1 knockout construct

A knockout strategy was designed to replace the only coding exon of mRMI1 (exon
3) with a neomycin selective cassette. A two-step approach was used in generating
the knockout construct. First, two DNA fragments located upstream and downstream
of RMI1 coding sequence were chosen as recombination targeting arms,
respectively. The 4.5kb fragment was referred to as ‘long arm’, whereas the 1.7kb
one was named as the ‘short arm’, respectively. The two arms were cloned into its
own specific vector separately. Second, the two arms with selective markers were
rejoined together to form the final knockout construct.
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1.2.1 Generating long arm and short arm plasmids

1.2.1.1 Shotgun cloning and identification of long-arm plasmid

Long arm sequence was obtained by direct digestion of the 444B20 BAC DNA with
BamHI. Digested BAC DNA fragments were then randomly ligated with pBS-PGKneo-bpA-LoxB vector. To select colonies carrying the desired fragment, an in situ
Southern blotting was performed. First, E. coli transformed with random ligated
plasmid were allowed to grow over night on LB plates and establish colonies. These
colonies were transferred onto filter membranes and lysed directly on them by lysis
buffer (0.5M NaOH, 1.5M NaCl). Filter membranes were then neutralized by
neutralization buffer (1.5M NaCl, 1M Tris, PH=8.0) and washed by 2X SSC before
crosslinked to the filter by UV. Next, Southern probe (long arm probe) was amplified
by PCR (primers: long arm probe upper: 5’CTTGGCTGTCCTGGAACTCTGT; long
arm probe lower: 5’AATGGTTACCCAGGAGCCACTA), labeled with α-p32-dCTP,
and hybridized with filter membranes at 650C overnight. Positive colonies carrying
the long arm insert picked. These colonies went on further restrict endonuclease
analysis to select the ones with the desirable orientation of cloning.
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1.2.1.2 Direct cloning of short arm plasmid

Short arm DNA with embedded PvuII site at its 5’ was PCR amplified using BAC
DNA as template. The primers are: short arm upper,
5’GTAAAGGGGTGGTGCTGGAATTG; short arm lower,
5’GCATGGCACTAACAACCACAGGA. PCR product was digested by BglII and
cloned into pMCI-TK-pA vector.

1.2.2 Construction of final knockout construct

The long arm and adjacent neomycin cassette sequence was released from long
arm plasmid by EcoRI/NotI digestion. This fragment was then cloned into the short
arm plasmid linearized by SpeI/NotI digestion. The final knockout construct contains
two recombination targeting arms, a Cre-floxed neomycin cassette in between two
arms and a TK selective marker at 3’ of short arm. After recombination, the neo
cassette is able to replace entire coding sequence of RMI1, while the TK marker
does not integrate into genome.

1.3 Identification of Rmi1 mouse ES cell clones
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The construct was transfected into mouse TC1 and G4 ES cells by the Genetically
Engineered Mouse Facility (GEMF) at MDACC. Tc1 and G4 ES cells are derived
from 100% 129S6/SvEvTac and 50% 129S6/SvEvTac/50% C57BL/6Ner genetic
background, respectively. Single ES cells were individually picked into 96-well plates
and allowed to form colonies. Then, genomic DNA from each colony were extracted,
prepared and hybridized with southern probe for genotyping. Two Southern blot test
strategies, which respectively target 5’ and 3’ DNA sequence of the knockout allele,
were utilized in genotyping. The procedures of Southern blot genotypings will be
described later in this chapter. In first round of ES cell colony screening, only the 5’
strategy was applied. Initially, about 10 colonies from each plate were tested as
Rmi1+/- ES cells. These Rmi1+/- colonies were transferred into larger plates, and
were subjected to Southern blot tests from both ends again before blastocyst
injections.

1.4 Germline transmission

The chimeras were generated by Engineered Mouse Facility (EMF) at MDACC.
They were then backcrossed with the C57BL/6 inbred mouse strain for at least 5
generations. Theoretically, genetic material from the original stem cells was reduced
to less than 5% thus these experimental mice should be considered as cogenic
ones.
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1.5 Southern blot tests form ES cell genotyping

Two probes, Probe1 and Probe3, were used in Southern blot genotypings of G-418
resistant ES cell colonies from either 5’ or 3’ end, respectively. Both probes were
amplified by PCR (primers: Probe1A, 5’CCGCCTTTGGTCGTGACTGACAAC;
Probe1B, 5’GCTCGGCGGACCTGTTAACACCAG; Probe3A,
5’CTGTGGCTAGAAAGATGGTTCAGC; Probe3B,
5’GAGGGCATGGCCCAGACTTG). For 5’ end Southern blot genotyping, genomic
DNA of ES cell colonies were directly propagated and digested with NheI overnight
in 96-well plates before transferred onto membrane and hybridized with p32 labeled
Probe1 overnight at 63oC. For 3’ end genotyping, while other conditions remain the
same, Probe3 was incubated with PvuII digested genomic DNA and the overnight
annealing temperature was 65oC.

1.6 PCR for mice and embryo genotyping

1.6.1 Preparing of Genomic DNA from mice samples

Mice genomic DNA was extracted and purified from mice tissues, usually toes or tail
tips. Tissues were first lysed by incubating overnight at 55oC with the mixture of 250
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uL lysis buffer (10nM TrisHCl ph8.0, 100mM NaCl, 2.5mM EDTA, 0.5%SDS) and
10uL Proteinase K (20ug/mL). Then, proteins and cell membrane debris were
precipitated by 100uL tail salt buffer (4.21M NaCl, 0.63M KCl, 10mMTrisHCl PH8.0)
and spinned down at 10,000 rpm for 10 minutes at 4 oC. Genomic DNA then was
concentrated by 400uL EtOH and centrifuged at 14,000 rpm for 15 minutes at 4 oC
followed by washed with 70% EtOH and dissolved in 200uL ddH2O.

1.6.2 PCR genotyping strategy of RMI1 mice

For PCR genotyping of RMI1 mice, two pairs of primers were used: LWT3A, 5’
CTTTAAGTATCGCCCTCCGTTTTG;
LWT3B, 5’CTTAACATGCCATGTTGCCAAAAG; NS3A, 5’
AGCAAGGGGGAGGATTGGGAAGACA; NS3B,
5’GCGGAGCTGCCCCAGCTTTAAGCT. Annealing temperature was set at 61 oC,
while the annealing time was 30 seconds for each round.

1.6.3 PCR genotyping strategy of p53 mice

For PCR genotyping of p53 mice, three primers adapted from Genetically
Engineered Mouse Facility at MDACC were applied: X6,
5’AGCGTGGTGGTACCTTATGAGC; 7, 5’GGATGGTGGTATACTCAGAGCC;
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neo19, 5’GCTATCAGGACATAGCGTTGGC. Annealing temperature was set at 55
o

C, while the annealing time was 45 seconds for each round.

1.6.4 Genotyping strategy of RMI1 blastocysts

E3.5 embryos were harvested by flushing uterus with 1X PBS. A nested PCR
strategy was applied for genotyping. Two pairs of primers were used in first round of
PCR: LWT1A, 5’CTCATCCCAGAGTAAGGTGGCCGACTAT; LWT1B,
5’CACAAGCTTCCAGCCACATTGGAGGTAC; NS2A,
5’TTCGCAGCGCATCGCCTTCTATCG; NS2B,
5’AGCAGGGTCTCGCCTTTTGCCTCGAGAG. The primer pairs, LWT3 and NS3
were used in the following second round PCR.

1.7 Cell culture and Clonogenic survival assay

Cell strains were maintained in 10% heat-inactivated fetal bovine serum and grown
in a humidified 5% carbon dioxide (CO2)-containing atmosphere at 37°C.
Procedures of Rmi1 siRNA knockdown and Clonogenic assay were applied as
described previously (82). Briefly, HCT116 cells were transient transfected with
either Rmi1 or control (luciferase) shRNA before counted and seeded onto 100mm
plates. Colonies were allowed to grow for 2 weeks before counting.
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2.0 Results

2.1 Generation of RMI1 knockout mouse model

We generated a RMI1 knockout mouse strain by replacing its exon 3, which contains
the entire RMI1 coding sequence of 1.8 kb, with a Cre-floxed neomycin selective
cassette. This replacement created a null-allele of RMI1 (Figure 5A.).

ES cells carrying one copy of the targeted allele were selected through several
rounds of Southern blot genotypings, using probes locating on either 5’ or 3’ of the
long and short arms, respectively (Figure 5B.). Screening of a total of 192 ES cell
clones showed that my general targeting frequency is 12%. RMI1+/- clones identified
by both 5’ and 3’ probes were used to generate chimeras through standard
blastocyst injection. After successful germline transmission, RMI1+/- founders were
genotyped by PCR and backcrossed to C57BL/6 background for at least 5
generations (Figure 5C.).
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2.2 Embryonic lethality of RMI1-/- mice

A small group of RMI1+/- mice was put on long-term observation for up to 3 years.
These mice do not display any noticeable defects in fertility, life span and
spontaneous tumor onset. However, intercross of Rmi1+/- mice did not produce any
mice with RMI1-/- genotype, indicating an Rmi1-dependent embryonic lethality.

To determine the time of embryonic lethality, I dissected pregnant females after
RMi1+/- mice intercrossing. First, attempts to recover RMI1-/- MEF cells from 13.5 dpc
embryos failed, as only wild type and RMI1+/-, but not RMI1-/- MEF cells were
collected from all MEF cells established. Subsequently, more females were
dissected at different stages of pregnancy. However, no RMI1-/- embryos were
identified as early as 7.5 dpc. To further investigate this question, I performed
blastocyst analysis. At day 3.5 dpc, neither abnormal nor RMI1-/- blastocysts were
identified from RMI1+/- crossing (Table 1.).

At the same time, the wild type and RMI1+/- embryos recovered from both embryo
dissection and blastocyst flushing displayed a nearly perfect 1:2 ratio, which strictly
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Date

+/+

+/-

-/-

E3.5

7

11

0

E8.5

11

18

0

E9.5

6

12

0

E10.5

2

6

0

Summary

19

36

0
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followed the Mendelian segregation. From these results, I concluded that RMI1 is
required for early embryonic development, and deleting both alleles of RMI1 leads to
embryonic lethality before implantation.

2.3 p53-dependent cell proliferation in Rmi1-depleted cells

We next investigated the mechanism of Rmi1-dependent embryonic lethality.
Knockdown Rmi1 in tissue culture cells destabilized the BTB complex and enhanced
the SCE level. Nevertheless, cells transfected with shRNA vectors were unable to
form colonies. We suspect that the increased genomic instability from lack of Rmi1
might be the primary cause of cell lethality.

To address this hypothesis, I performed the clonogenic survival assay. I transfected
Rmi1 shRNA as well as control RNA (luciferase) into both HCT116 and its isogenic
p53-null strains. Clonogenic survival assays were conducted after transient
transfection and G418 selection. In accordance to our previous data (81),
knockdown Rmi1 resulted in drastic decrease in colony survival rate. p53-null
background per se had little effect on colony formation when transfected with the
control luciferase shRNA construct. Interestingly, absence of p53 in Rmi1 depleted
cells significantly rescued its colony formation ability, as colony survival increased by
10-fold when comparing with that from Rmi1-depleting cells alone (Figure 6A, B.).
This data strongly argues for a potential functional relationship of RMI1 and p53 in
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regulating cell viability. Most likely, lack of p53 allows cells to continue to proliferate
when genomic lesion are accumulated as a result of Rmi1 loss.

2.4 p53-/- did not alleviate early embryonic lethality of RMI1-/- mice

Since p53-/- background effectively mitigated the cellular lethality of Rmi1 knockdown
cells, it is likely that deletion of p53 alleles may extend RMI1-/-embryos’ life span to
beyond the implantation stage. This observation would suggest that loss of RMI1
leads to genomic stresses that are dealt with by the p53-dependent pathways. To
address this possibility, I performed embryonic analysis on D3.5 blastocysts
collected from p53+/-RMI1+/- intercrossing. Of all 47 blastocysts collected, 17 were
RMI1+/+ and 28 were RMI1+/-. None of them, however, was RMI1-/-. This result
indicates that deleting either one or both alleles of p53 is unlikely to extend viability
of RMI1-/- embryos passing the implantation stage. (P<0.05), suggesting a high
degree of severity resulting from RMI1 deletion.
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3.0 Discussion

3.1 RMI1 is essential for early embryonic development

The RMI1 knockout mouse model allowed us to investigate its function in embryonic
development. Our data demonstrated that RMI1 is required for embryo viability.
Complete deletion of this gene led to early lethality before implantation stage.
Our finding, together with previous studies, shows that all three conserved
components of BTB complex, including BLM, Topo3α and RMI1, are required for
embryonic development. However, their phenotypes of lethality are distinct. BLM-/embryos die at 13.5 dpc whereas Topo3α-/- embryos die before implantation stage.
In our study, we’ve demonstrated that similar to Topp3-/- ones, RMI1-/- embryos die at
the same, if not earlier, embryonic stage.

The mechanism that leads to RMI1-dependent lethality remains unknown. To our
best knowledge, until recently, no catalytic activity had been identified for Rmi1. It is
very likely that Rmi1 performs a non-catalytic, regulative function in the BTB
complex. Thus, the lethality of RMI1-/- embryos could be contributed to relationship
between RMI1 and BLM/Topo3α. Physical presence of Rmi1 is required for BLMTopo3α complex stability and activity, which has been evidenced by Rmi1
knockdown experiments. Based on that, it is reasonable to believe that complete
absence of Rmi1 could further diminish stability of BLM and Topo3α proteins,
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possibly under threshold of maintaining their proper cellular functions. The lethality
of RMI1-/- embryos, under this scenario, is the compounded consequences of both
functional and physical deficits of BLM and Topo3α.

It is notable that in comparing with BLM, Topo3α might play a major role in RMI1dependent embryonic lethality. This view is supported by previous experiments.
First, Topo3α protein levels could be more significantly affected by RMI1 knockout.
Previous studies from our and Dr. Weidong Wang’s lab suggest that depleting Rmi1
results in moderate and drastic decrease of protein level of BLM and Topo3α,
respectively, which indicates that the Topo3α protein is more likely be reduced to
insufficient levels than BLM. Secondly, defective BLM function alone does not
explain early lethality of RMI1-/- embryos. BLM-/- embryos show retarded growth and
die at 13.5 dpc. Thus, the absence of BLM protein alone may not be the cause of
this pre-implantation lethality. On the other hand, the lethal phenotype of Topo3α-/embryos is reminiscent of that of RMI1 mice. This similarity of phenotypes could
indicate a functional relationship of RMI1 and Topo3α.

RMI1-/- embryos could die from mitotic dysfunction. Rmi1 is found in two independent
complexes. One is the BTB complex. The other one contains only Rmi1/2 and
Topo3α without BLM. This indicates that Rmi1 and Topo3α together may have
cellular function other than ‘resolution’ in HR. Nevertheless, yeast top3 mutations
exhibited sporulation and chromosome separation defects during mitosis. Moreover,
knockdown Topo3α in mammalian cells led to abnormal anaphase bridge
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formations. It is plausible that RMI1 deletion leads to defective mitotic function due to
insufficient protein level of Topo3α, and eventually, cell death.

However, it is still unclear whether RMI1 itself has any direct role in maintaining
embryo viability. Although Topo3α-/- embryos also die before implantation, normal
deciduae (Topo3α+/- and wildtype) as well as smaller ones contained no organized
embryos were dissected from Topo3α+/- intercrossing. On the other hand, we have
not found any of such deciduae from RMI1+/- intercrossing, suggesting a possible
earlier lethality of RMI1-/- embryos in comparison with Topo3α-/- ones. The earlier
lethality of RMI1-/- embryos could be caused by compounded outcome of defective
activities from both BLM and Topo3α. It is also possible that besides its regulative
role with BLM and Topo3α, RMI1 yields unknown function in maintaining cellular
viability.

3.2 Functional relationship of Rmi1 and p53

p53 is one of the most active regulators in DNA damage-induced cell cycle arrest
and apoptosis pathways. The protein-protein interaction between p53 and BLM has
been revealed, whereas an N-terminal region of BLM is mapped as respective
interaction segment for p53 binding. P53 may regulate BLM function during
homologous recombination (HR) pathway, where it could interact with DNA
recombination intermediates and prohibit helicase activity of BLM. Interestingly, p53
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is dependent for DNA damage-induced apoptosis in BS cells. Additional deleting of
p53 rescues cell death of BS cells followed UV or MMC treatments. Because of the
close relationship between BLM and Rmi1, p53 may also play a significant role in
RMI1-associated cellular viability.

In our experiment, we have demonstrated that p53-null alleviates cellular lethality of
Rmi1 depleting cells. However, deleting p53 alleles in RMI1-/-embryos did not extend
their viability beyond the implantation stage. A plausible explanation is that the
genomic integrity is more strictly required during embryonic development. These
results strongly argue for our hypothesis that Rmi1 depleting cells die from
compromised genomic integrity.
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Chapter III

RMI1 Heterozygosity Accelerates Induced-tumor
Formation of p53+/- Mice

1.0 Materials and Methods

1.1 Ionizing radiation treatment and tumor analysis of animal model

Littermates from Rmi1+/-p53+/- intercrossing were subjected for IR irradiation at
4GY (NASAtron) around 6 weeks of age. A daily observation was applied to all
irradiated mice for at least 1 year or until death. Those with visible tumor
phenotypes were sacrificed and sent for necropsy. Tissue samples were preserved
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in 10% formalin. For histopathological analysis, samples were embedded in paraffin
cassettes prior to slide cutting and staining by hematoxylin&eosin (H&E). KaplanMeier methods was applied to estimate survival rate. Survival curves and P value
calculation were carried by software GraphPad Prism.

1.2

Extraction of genomic DNA from fixed specimens

Pieces of mouse tissue samples fixed by 10% formalin were first washed by running
water overnight, then, chopped into fine pieces by scissors in 1.5ML tubes. Next, as
previously described, standard genomic DNA extraction protocol was applied.
Genomic DNA was dissolved in 50uL ddH2O.

1.3

Preparation MEF cells

Females were euthanized at day 13.5. The ovaries were transferred into 10cm
tissue culture dishes and washed with 1X PBS containing 2X pen/strep under
sterilized environment. Each embryo was transferred into a new dish, removed from
all mother tissue, and minced well with a surge knife. The embryo was then
incubated with 1 ml 0.25% Trypsin/EDTA at 37 ºC for 10 minutes, added with 10 ml
DMEM with 10% FBS, mixed by gently pipetting the medium 10 times and placed at
37 ºC with 5% CO2 for 24 hours. The MEF cells were spited or frozen when
confluent.

59

1.4

Immuno-staining of radiation-induced foci

MEF cells were allowed to grow on cover slips and irradiated at 1.5Gy at desired
time points. The cover slips were washed once with 1X PBS, fixed by 1ml 3%
Paraformaldehyde for 10 minutes at RT. The slips then were washed once with
1XPBS, treated with 1ml 0.5%Triton buffer for 5 minutes at RT, and washed twice
with 1X PBS. The primary antibodies, diluted in 1:1000 ratio with 5% Goat Serum,
were applied directly at the center of slips and the slips were incubated overnight at
4 ºC. The secondary antibody, diluted in 1:2000 ratio with 5% Goat Serum, were
applied and incubated for 20 minutes at 37 ºC. All the antibodies are kindly gifts from
Dr. Junjue Chen of MDACC. A drop of Mounting medium was applied to each slip
before it was fix to a slide by sealing all edges with nail varnish.
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2.0 Results

2.1 Shortened half-life of radiation-induced foci in p53+/-RMI1+/- MEFs

The BTB complex is known to maintain genomic integrity through the HR pathway
during DSB repair. The impact of RMI1 deficiency on genomic integrity may further
be facilitated under a p53+/- background. Therefore, I tested the radiation-induced
foci status in p53+/-RMI1+/- MEFs. The control MEFs, consisted of wild type, p53+/-,
and RMI1+/- genotypes, were derived from littermates of p53+/-RMI1+/- intercrossing.
To do so, I obtained intercross between p53+/-RMI1+/- males and females and
harvested embryos at D13.5. Four MEF cell lines were generated from littermates
with the following genotypes, p53+/+RMI1+/+, p53+/-RMI1+/-, p53+/+RMI1+/-, and
p53+/+RMI1+/-.
All the MEFs were subject to 1.5Gy of ionizing radiation. The nuclear focus formation
was stained by either γ-H2AX or 53BP1 antibody and scored at various time points
up to 48 hours after radiation. Initially, the numbers of foci observed per cell were
similar among p53+/-RMI1+/- and control MEFs. (Figure 7.) However, after 24 or 48
hours, the average number of foci per p53+/-RMI1+/- MEF nucleus is moderately
lower than any of the control MEFs.
It is more noticeable that at 24 or 48 hours post IR, a substantial proportion of cells
had already lost detectable foci and became foci-negative. This phenomenon was
observed from MEFs of all genotypes. However, when comparing with control MEFs,
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p53+/-RMI1+/- MEFs had a significantly higher percentage of foci-negative population.
(Table 2.) While the foci-negative p53+/-RMI1+/- MEFs constituted more than 60% of
the total population, the percentages of foci-negative control MEFs were between
25~45%. This result suggests an accelerated resolvation of radiation-induced foci in
p53+/-RMI1+/- MEFs, presumably due to the partial loss of RMI1, which allows
Holliday junctions to be resolved without the deterrence of the BTB complex function
and in conjunction with the deficient p53 status.

2.2 Ionizing radiation fails to induce enhanced tumor formation in RMI1+/- mice

The BTB complex proteins are known for their function in maintaining genomic
integrity partly by preventing chromatid exchanges during HR. Because of its role in
this complex, it is very likely that loss of one RMI1allele could affect the overall level
of the BTB complex activity. This disruption might impact the efficiency or/and
outcome of DSB repair, because elevated recombination events may cause LOH in
tumor suppressor gene alleles, and consequently, lead to increased tumorigenesis.
Moreover, as indicated by my results at the cellular level, p53 deletion effectively
mitigated the cell lethality caused by Rmi1 depletion. Thus, it is possible that
compromised p53 function may facilitate or enhance any potential haploinsufficiency
of the Rmi1 gene. Following this idea, I constructed RMI1 and p53 double
heterozygous mouse model. I exposed RMI1+/- as well as wild type, RMI1+/-p53+/and p53+/- mice to sub lethal dosage of IR. Four groups of mice were treated with
4Gy of gamma radiation at an age of 6 weeks. These mice were then kept for
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Hours after
IR

Rmi1

+/-

Rmi1+/p53+/-

p53+/-

Wild type

24h

27.8±3.2%

66.4±12.5%

41.6±7.5%

48.8±4.3%

48h

28.4±5.0%

80.6±7.0%

56.7±4.3%

45.8±10.6%

24h

24.6±5.4%

61.7±9.1%

35.6±11.3%

15.3±23.2%

48h

28.3±2.4%

60.4±6.4%

38.5±8.7%

29.5±6.1%

53BP1

H2AX
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observation of tumor formation for at least a year. All the mice were euthanized at
the end of the tumor monitoring. As shown in Table 3, although more mice
developed tumor before 35 weeks of age, the overall tumorigenesis rate of RMI1+/mice (23%, 5/22) is indistinguishable from that of wild type controls (31%, 8/26).
Thus, RMI1 heterozygosity alone seems unable to cause increased tumorigenesis,
both spontaneous and induced.

2.3 Rmi1 heterozygosity accelerates IR-induced tumor formation of p53+/- mice

Expectedly, the majority of p53+/- mice developed tumors (75%, 15/20). Interestingly,
although overall tumorigenesis rate of RMI1+/-p53+/- (83%, 19/23) mice is close to
that of the p53+/- mice, more mice from this group developed tumors at earlier ages
than p53+/- ones. The tumor incidence is 52% (12/23) by 35 weeks of age, and 74%
(17/23) by 55 weeks of age, respectively. In comparison, percentages from p53+/group are 10% (2/20) and 50% (10/20) by the same time points, respectively.
Moreover, the average tumor free rate is 27 weeks from RMI1+/-p53+/- mice,
comparing with 45 weeks from p53+/- ones. The difference of average tumor free rate
from two groups is statistically significant (P<0.02) (Figure 8.). Clearly, our result
indicates a relationship between p53 and RMI1 in accelerated tumorigenesis.

Previous studies have shown that irradiated p53+/- mice develop lymphoma as
primary tumor. Depending on the background of the inbred strains, 48% to 90%
induced tumors from p53+/- mice are lymphoma. In our experiment, a similar trend
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was observed. Lymphoma consisted the primary source of identified tumors derived
from p53+/- mice.

No. of
No. of

mice

mice

died

died

within

No. of
lymphoma sarcoma sarcoma unknown

mice
35 wks
Rmi1+/p53+/-

23

29

12

12

5

4

1

20

25

2

7

3

3

5

22

7

3

3

2

0

2

26

9

1

8

2

0

1

Rmi1+/+
p53+/Rmi1+/p53+/+
Rmi1+/+
+/+

p53
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(47%, 7/15), more than carcinoma and sarcoma combined. On the other hand,
RMI1+/-p53+/- mice developed higher percentage of lymphoma (57%, 12/23) (Table
3.). However, it requires further study to determine whether the difference of
lymphoma occurances from the two groups is statistically significant. Together, the
additional deletion of RMI1 does not seem to alter the overall tumor spectrum of the
p53+/- mice.

Interestingly, in comparison with p53+/-, RMI1+/-p53+/- mice exhibited higher risk to
aggressive tumor types, which include high grade lymphoma, invasive carcinoma,
and invasive osteosarcoma as illustrated in Figure 9A-F. In summary, deleting one
copy of RMI1 gene under p53+/- background leads to accelerated tumor onset and
potentially more aggressive tumor types, both of which indicate a tumor suppressor
role of RMI1.

2.4 LOH assays on RMI1 and p53 loci

Loss of heterozygosity (LOH) of p53 locus occurs frequently in p53+/- tumors. It is
very likely that LOH on RMI1 locus may cause accelerated tumor formation in
RMI1+/-p53+/- mice. In this project, I tested this hypothesis by studying LOH on both
loci. Genomic DNA from tumor tissue and tail tips of RMI1+/-p53+/- mice are collected
and PCR genotyping was performed. Interestingly, whereas tumor cells lost wild
type p53 alleles, the heterozygosity of RMI1 locus sustained (Figure 10A.). Thus,
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LOH of RMI1 locus seems not the cause of tumor-formation phenotype observed in
RMI1+/-p53+/- mice. However, because genomic DNA extracted from fixed tumor
specimens were unable to produce clear PCR results (Figure 10B.), probably due to
fragmentized genomic DNA, more data is needed in order to firmly establish this
hypothesis.
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3.0 Discussion

3.1 Functional relationship between p53 and RMI1

I have shown that radiation-induced foci were more rapidly resolved in RMI1+/- p53+/MEFs, when compared to MEFs derived from wild type, RMI1+/- p53+/+,, and RMI1+/+
p53+/- embryos. This accelerated resolving rate is unlikely caused by cell death,
since no significant difference was found among MEF cells with the fours different
genotypes when assayed for radiation-induced apoptosis with the same dose of
radiation.

While p53-deletion mitigated cell death of RMI1-depleted cells, p53-/- background
fails to extend the viability of RMI1-/- embryos to blastocyst stage . In the foci
experiment, however, p53 and RMI1 double heterozygous MEFs displayed a
measurable phenotype compared to control MEF cells, indicating a functional
interaction between p53 and RMI1. These results refect the abilities of different
experimental systems when genetic interactions are investigated. It also suggests
that the requirement for RMI1 and p53 functions is not identical among transformed
cell, MEF cells, and mouse embryos. However, the commonality in the observed
phenotypes is consistent with the notion that the BTB complex acts to facilitate noncrossover HR repair and prevent excessive or nonreciprocal exchanges. Thus, RMI1
deficiency in general will lead to genomic instability of varying extent. A p53 deficient
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background likely substantiates the defects by suppressing checkpoint mechanisms.
However, the exact role of p53 in association with RMI1 remains unknown.

3.2 Recessive haploinsufficiency of RMI1+/- mice

RMI1+/- mice are viable and productive. At the same time, deleting one copy of RMI1
allele does not lead to either spontaneous or radiation induced-tumor formations.
Challenged by IR of 4 Gy at 6 weeks of age, 3 RMI1+/- mice died within 35 weeks. By
the end of the experiment, 7 deaths were observed out of 22 individuals. In
comparison, these numbers are 1 and 9 out of 26 in wild type control cohort,
respectively. The tumor-free survival curves from two cohorts are not significant
different within either 35 or 55 weeks of period. RMI1 heterozygosity does not alter
the tumor spectrum, too. Both mice mainly developed lymphoma and sarcoma.
Although the percentage of lymphoma incidences from RMI1+/- mice was much lower
than that from wild type ones, it could be simply due to insufficient sample size.

These results are consistent with phenotypes observed from both BLM and Topo3α
heterozygous mice. However, haploinsufficiency has been observed in BLM mice.
BLM+/- mice die earlier when injected with murine leukemia virus (MLV).
Furthermore, the BLM/APC double-heterozygous mice exhibited enhanced
gastrointestinal tumor formation. Thus it is very likely that RMI1 mice could display
similar haploinsufficient cancer-prone phenotypes under certain condition.
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We approached RMI1 function in tumorigenesis by crossing RMI1+/- mice with p53+/ones. Interestingly, the RMI1/p53 double heterozygous mice, unlike RMI1+/- and
p53+/- ones, exhibited accelerated radiation induced-tumor formation. At the age of
35 weeks, 12 out of 23 RMI1+/- p53+/- mice had died, whereas only 3 out of 22 and 2
out of 20 mice died from RMI1+/- and p53+/- groups, respectively. This early tumor
onset indicates a recessive haploinsufficiency of RMI1 function in tumor
susceptibility.

Despite accelerated tumor onset, RMI1+/-p53+/- mice did not display altered tumor
spectrum from p53+/- mice. p53+/- mice received sub-lethal dosage of IR are known
to be prone to a wide spectrum of tumors. Although the profiles of tumor spectrum
might vary depending on strains and radiation dosage, lymphoma is the primary
source of tumor types. In our study, about half of IR induced-tumors from p53+/- and
RMI1+/-p53+/- mice consisted of lymphoma. Moreover, both mice developed sarcoma
and carcinoma.

It is notable that RMI1+/-p53+/- mice had increased risk to aggressive tumor types. In
our limited study, we have observed high-grade lymphoma, invasive carcinoma and
invasive osteocarcoma. In contrast, few mice from p53+/- as well as other two groups
developed such high-grade tumors. It is thus very likely that in addition to
accelerating tumor onset, RMI1 heterozygosity, in combination with p53+/-, might
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facilitate the progression of malignancies, too. However, in order to firmly establish
this point, further study involved larger sample pool may be required.

The mechanism between RMI1 heterozygosity and earlier tumor onset of p53+/- mice
remains elusive. LOH of p53 locus is a common phenotype of p53+/- tumors. Our
preliminary study of LOH in RMI1+/-p53+/- tumor samples suggested that while the
wild type p53 allele was lost, the wild type RMI1 allele, on the other hand, was not.
BS cells are known for its elevated gene targeting/recombination efficiency,
indicating BLM, as well as BTB complex function in maintaining genomic stability
and integrity. It is very likely that RMI1 heterozygosity reduces BTB complex activity,
and leads to promoted genomic recombination events. Thus in RMI1+/- cells,
although the cellular viability and DNA damage checkpoint/repair pathways may
remain intact, LOH on p53 locus could be facilitated by this RMI1-associated
enhanced recombination efficiency. This results in accelerated tumor onset.

In summary, we argue for a potential tumor suppressor role of RMI1. Although
deleting one copy of RMI1 gene did not lead to increased risk of both spontaneous
and induced tumor formation in animal model, it facilitated tumor onset when
coupled with p53 heterozygosity.
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3.2 Potential clinic application of RMI1 mouse model

Until recently, RMI1 gene has not been linked to any specific genetic disorders. Our
experiment, however, demonstrated that RMI1+/- in combination with p53+/-,
contributes to significant accelerated radiation-induced tumorigenesis. This result
suggests RMI1 heterozygosity, when coupled with defective tumor suppressor
genes, could lead to higher risk, earlier onset and poorer outcome of tumors. Thus,
because its haploinsurfficient impact on tumor susceptibility, RMI1 should be
considered as an tumor suppressor gene.

Recently, the clinical outcome of single nucleotide polymorphisms (SNPs) has been
studied extensively. By definition, polymorphism is the least common allele occurring
in 1% or greater of the population (113). SNPs are present throughout human
genome. The average frequency of SNPs is approximate 1 per 1,000 base pairs (bp)
(114). It is well established that certain SNPs are associated with cancer
susceptibility. Depending on the context of the SNP, it could be either protective or
provocative in cancer risk (115, 116).

Several SNPs from RMI1 gene have been linked with increase risk of cancers in
clinical studies. In predominating Swedish population, SNP (rs1982151) carriers
have about 2-fold and 1.5-fold higher risk of AML/MDS and MN than controls,
respectively. This association between risk of cancers and RMI1 SNP is observed
both in heterozygotes and homozygotes. Moreover, the effect of age was found

82

during this study, especially in MN patients (117). Later, SNP (rs296887) of RMI1
was also identified to be associated with increased cancer risks for AML/MDS and
MN, but not bladder cancer (118). The result from SNP studies of RMI1 is consistent
with that from our mouse model, that RMI1 has potential function as a tumor
suppressor gene. Taking together, RMI1, as a tumor suppressor gene, may have its
potential applications in further cancer prevention and treatment.
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Chapter IV

Conclusion and Future Directions

1.0 Conclusion
In this project, I have successfully established a knockout mouse model of RMI1
gene. I have shown that RMI1 is essential for early embryonic development.
Deleting both alleles of RMI1 leads to embryonic lethality before implantation. I have
also demonstrated that whereas RMI1+/- mice are viable and exhibit no obvious
phenotypes, RMI1 heterozygosity, facilitates IR-induced tumor formations in p53+/background. The earlier onset and more progressive outcome of tumors from
RMI1+/-p53+/- double-heterozygous mice suggest a potential role of RMI1 in tumor
suppressing.

I have also investigated mechanisms of RMI1-associated cell death. Additional
depleting of p53 restored colony formation ability of Rmi1 knockdown cells,
indicating p53 and RMI1 are functionally related in regulating cellular viability. The
exact mechanism of RMI1, however, needs further investigations.
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2.0 Future Directions

2.1 Study molecular modification of RMI1

Post-transcriptional modification plays an important role in regulating protein
activities. Among the three key components of the BTB complex, molecular
modification on BLM has been studied extensively. BLM is phosphorylated at The99
and Thr122 during mitosis and in response to genotoxic stress (20, 35, 37, 119). This
phosphorylation is ATM/ATR dependent. Expression BLMT99G and BLMT122A in BS
cells were able to restore normal frequency of SCE, but failed to correct
radiosensitivity. BLM is also a substrate for SUMO modification (28). BLM mutations
with abolished SUMO modification sites (K317 and K331) failed to localize to PML
NBs, yet partially complemented the genomic instability phenotypes (120). It is
possible that modifications may also be required for tight regulation of RMI1 activity.

Chang from our lab has identified Ser284 and Ser292 as two phosphorylation sites
on Rmi1. Rmi1 is phosphorylated after UV, HU or IR treatment. This
phosphorylation, unlike BLM’s, is independent of ATM/ATR. Although the functional
significance of RMI1 phosphorylation remains to be elucidated, it is of particular
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interests to explore its role in coordinating RMI1 as well as BTB complex activity in
response to DSBs. By utilizing the same strategy of RMI1 knockout, we could
manage to establish a knock-in model of RMI1 with mutated phosphorylation site.
This model, if available, would serve as the best tool to study function of RMI1
phosphorylation.

2.2 Study functional domains of RMI1

Structurally, several functional domains and evolutionary conserved regions have
been identified in RMI1 protein. Whereas activity of certain domain remains
controversial, the N-terminus of RMI1 is required for BLM and Topo3α interactions.
RMI1 mutations abolishing Topo3α binding activity was unable to alleviate
clonogenic survival of RMI1 depleted cells, suggesting a functional importance of
this region. Despite recent progress, understanding of functions of other
domains/regions is still limited. For example, RMI1 is proposed to recruiting BLM
and Topo3α onto DNA substrate and to facilitate their activity. However, the exact
mechanism of Rmi1 in this process has yet identified. Further study on dissected
functions of RMI1 by truncations or point mutations could illustrate RMI1 activity, and
help us better reveal its function.
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2.3 Study potential protein partners of RMI1

Physical and functional interactions between RMI1 and BLM/Topo3α have been
unfolded. Recently, the third protein binding to RMI1, RMI2, has been identified. Still,
it is possible that potential RMI1-interacting proteins are yet to be found. Moreover,
the kinase and phosphotase in response to Rmi1 phosphorylation remain unknown.
Thus, searching for potential protein partners of Rmi1 would help in understanding
RMI1 function and its exact role in BTB complex regulation.

2.4 Study RMI1 mutations/SNP in human cancers

Defective BLM causes Bloom syndrome. Since RMI1 is required for normal BLM
function (82), its mutations may also lead to tumor-prone genetic disorders.
However, several attempts have failed to detect such mutations. Recently, Broberg
and co-workers have established RMI1 SNPs that associate with increased risk of
cancers (117, 118). The two SNPs, locating at transcriptional and promoter regions
of RMI1 respectively, are linked to a 2-fold increase of certain types of cancers. This
finding, for the first time, established relationship between RMI1 and human cancer
susceptibility. Together with our findings from irradiated RMI1+/-p53+/- mice, it is
possible that polymorphisms or mutations of RMI1 could alter tumor risk and grade.
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A high volume screening of RMI2 SNPs and mutations in tumor samples could
further help us to reveal more information of cancer-associated RMI1 alleles. By
studying these alleles, we may be able to learn dissected protein function/activity of
Rmi1. Moreover, at least one SNP with increased cancer risk locates to the RMI1
promoter region. This SNP, as well as other potential ones, would help us to better
understand the regulation of Rmi1 expression. Furthermore, these alleles could
provide useful information in cancer prevention, diagnosis and treatment.
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Protein Interaction Network among
INO80 Complex Subunits

Introduction & Significance

1.0 Classification of chromatin remodeling complexes

The genomic DNA of eukaryotic cells is packaged into highly compacted and stable
chromatin structure, which helps to envelop it in the nucleus. The primary unit of the
chromatin structure is the nucleosome. It includes 146 base pairs of DNA, which
wraps about 1.7 left-handed turns around the histone octamer composed of two
H2A-H2B heterodimers and one H3-H4 tetramer. During genomic DNA packaging
process, it could be packaged into higher order structures termed chromatin fibers.
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Although nucleosomal structure alleviates the spatial constrain of the nucleus, this
compacted structure presents a barrier for proper DNA metabolic processes, as
these processes are impeded due to limited accessibility of DNA substrates. In order
to create dynamic chromatin environment and expose desired DNA substrates,
chromatin structure are reconfigured by two distinct yet highly intertwined
mechanisms, post-translational modification of histones and ATP-dependent
chromatin remodeling (121, 122) (Table 1, 2.).

The ATP-dependent chromatin remodeling complexes are named after their ATPase
subunits, all of which belong to the SWI/SNF family, a part of SNF2 superfamily.
These subunits could be further divided into subfamilies, including the SWI/SNF,
ISWI, CHD and INO80 (Table 2.). Among them, the INO80 subfamily is the most
recent identified family, which is conserved from yeast to mammals (123).
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2.0
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2.0 Cellular functions of INO80 complex
Previous studies have indicated that INO80 complex is involved in almost all DNA
metabolic processes, which include transcription, replication, and damage repair.
Interestingly, INO80 complex may also have function in checkpoint regulation (124).
In the following sections, INO80 complex function in different DNA metabolic
processes will be discussed briefly.

2.1 The INO80 complex in transcriptional regulation

The Ino80 ATPase was first identified as a transcriptional regulator. Initial
characterization suggested that it was required for inositol-responsive gene
expression (125). Later, evidences indicate that this protein, as well as its complex,
in response to a variety of signaling pathways, is able to regulate a limited set of
gene transcriptions in yeast, plants and mammals (126-128).

The function of INO80 complex in transcription regulation associates with
transcription factor YY1, which is an interaction protein of the human INO80 complex
(Figure 3.). Cai, Y et al. demonstrated that the INO80 complex is required for YY1
binding to two well-characterized YY1-activated genes, and deleting two subunits of
INO80 complex abolishes expressions of these two genes (128).
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2.2 The INO80 complex in DNA replication

Several recent studies have suggested that INO80 complex contributes to ensuring
replication fork progress during both normal and challenged situations. Yeast INO80
complex is recruited onto not only normal non-stressed, but also stalled replication
forks and unfired replication origins, both of which are induced by HU (126, 129,
130). Moreover, yeast strains with mutations of INO80 subunits exhibit a slower
growth phenotype (130), suggesting a defective DNA replication in the absence of
INO80 complex. Further studies show these strains are unable to efficiently restart
replication after stress and accumulate DSB, mainly due to dissociation of replication
machinery from stalled replication forks (126, 129). Based on these correlative
evidence, INO80 complex is proposed to promote remodeling or remove
nucleosomes in the path of replication forks, and possibly, reassembling them after
strand synthesis. However, this proposed mechanism of INO80 complex in DNA
replication remains to be proved.

2.3 The INO80 complex in DNA repair
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Deletions or mutations of INO80 complex subunits are hypersensitive to a variety of
reagents causing DNA damage, including methylmethane sulfate (MMS), ionizing
radiation (IR), ultraviolet (UV) and topoisomerase inhibitors (131, 132). These
observations indicate that the INO80 complex has a function in DNA repair.

Recently, progress has been made in understanding the INO80 complex’s role in
DSB repair. Yeast INO80 complex is known to be recruited to the vicinity of HOinduced DSB within 2 hours. This recruitment is partially dependent on phosphoH2A, since deletion of H2A is able to reduce this recruitment (133, 134). Further
investigations indicate that Arp4 and Nhp10, two subunits of INO80 complex,
contribute to phospho-H2A recognition. Deletion of either gene in yeast results in
reduced recruitment of INO80 complex subunits to DSBs (135). However, it is still
debatable whether Arp4 is dispensable in this recruitment, as it is reported that
INO80 complex stably binds to γ-H2AX in the absence of Arp4 (135).
Moreover, in mammalian cells, INO80 complex is associated with HR-mediated DSB
repairs. Depletion of either Ino80 or YY1 leads to substantial reduced HR activity
(132). The mechanism under this observation, however, needs further investigation.

In addition, INO80 complex may have its function in checkpoint response. Deleting
IES4, a subunit of yeast INO80 complex, leads to depressed p53 activation. In
contrast, phosphor-mimic mutant of this gene exhibits enhanced p53 activation and
slower S phase progression with MMS, whereas the repair machinery appears
normally (136, 137).
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3.0 Protein Components of INO80 Complex

The human INO80 complex was first isolated by the J Conaway laboratory (128,
137). Among the 15 subunits identified from this complex, 8 are orthologs of yeast
INO80 complex components. Because of their functional importance and evolutional
conservation, hereafter, these 8 proteins are referred as core subunits of INO80
complex. Moreover, 3 subunits, INO80, Arp5 and Arp8, are presented exclusively in
this complex, and are not found in other chromatin remodeling complexes. (Table
3.). Although the role of INO80 complex in DNA metabolism is implicated, functions
of individual INO80 subunits, other than the ATPase-helicase components Ino80,
remain largely elusive.

The Ino80 protein is generally considered as the key factor in this complex (Figure
1.). First, although it is not the only ATPase within this complex, its ATP hydrolysis
activity is required for this complex’s chromatin remodeling function (125, 131).
Second, Ino80 has physical interactions with several core INO80 complex subunits,
including actin, actin-related proteins (Arps) and Rvbs (124). Thus it may serve as a
docking station of INO80 complex (Figure 1.).
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The AAA+ ATPases Rvb1 and Rvb2 are evolutionarily conserved from yeast to
human, which shares sequence similarity to bacterial RuvB ATPase (138).
Structurally, the Rvb1/Rvb2 forms two stacked hexameric rings with 6 of each
protein (139, 140). Nevertheless, it is unclear whether these two proteins integrate
into INO80 complex with similar structure, although IP assays suggest they keep sixfold stoichiometry in INO80 complexes from both yeast and human (128, 131).
Although the exact function remains unknown, Rvb proteins may be required for
stable assembly of INO80 complex, as Rvb2 is required for recruitment of Arp5 to
the site of DNA double strand breaks (141).

Ino80 interacts with multiple Actin and Actin-related proteins, including Arp4, Arp5
and Arp8 (137). The docking sites of these proteins on Ino80 have been mapped. As
previously described, Arp5 and Arp8 are specifically presented in INO80 complex.
Based on observations of Arp-histone bindings, it is proposed that these Actinrelated proteins may contribute to nucleasome binding of INO80 complex (142, 143).
Protein interactions and their functions between other components of the INO80
complex remains unknown. Identification of these interactions will provide additional
understanding toward the INO80 complex structure and function.
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4.0 Bimolecular fluorescence complementation assay

The Bimolecular fluorescence complementation (BiFC) assay, first reported by Hu
CD et al. in 2002, is designed to detect protein-protein association in living cells
(144). In this assay, two putative interacting proteins were fused with non-functional
fluorescent protein fragments, respectively (Figure 2.). If taken into close distance,
the two fragments are able to resemble themselves and reconstitute functional
fluorophore. The fluorescent signal then could be visualized under microscopy,
which indicates the physical interaction of proteins. Comparing with traditional in
vitro interaction assays, BiFC is able to provide visualized images of interaction with
native proteins.

5.0 Goals of experiment

Despite that the core components of the INO80 complex have been identified and
some of the structure features of this complex have been revealed, the detailed
information of in vivo protein-protein interaction within this complex remains
unknown. Furthermore, functional study of its core subunits, especially, the
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biological function of nuclear ARPs in maintaining complex stability, needs further
investigation.

In this study, I investigate protein-protein interactions among the 7 conserved core
subunits of human INO80 complex using the BiFC assay. This experiment will
provide a comprehensive view of physical protein contact within the INO80 complex.
In addition, our lab has successfully developed Ino80 and Arp5 somatic conditional
knockout cell strains. In combination with these mutant strains, we may be able to
reveal Ino80 and Arp5’s function in maintaining stability of INO80 complex.
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Materials and Methods

1.0 Cell Culture and cDNA Cloning/Transfection

HEK293 and HEK293T cell lines were culture in DMEM medium, supplemented with
10% FBS. Cells were incubated in 37oC incubator with 5.5% CO2 concentration.
cDNA of Arp4, Tip49a, Tip49b and Ies6 were obtained from Human ORFeome V3.1
program, from which all cDNA was cloned into Gateway pDOR223 vector. The plate
numbers of 4 hORFeome cDNA clones are listed below: Arp4, D01-11037; Rvb1,
H06-11011; Rvb2, D01-11037; Ies6, D01-31001. cDNA of Ies2, Arp5 and Arp8 were
amplified by PCR and cloned into pDOR201 vector, respectively. The PCR primers
used in cDNA amplications were listed below: Arp5 upper,
ggggacaactttgtacaaaaaagttggcatggcggcgaacgtgttt; Arp5 lower,
ggggacaactttgtacaagaaagttgggtatgcctgctcaccagcac; Arp8 upper,
ggggacaactttgtacaaaaaagttggcatgacccaggctgagaag; Arp8 lower,
ggggacaactttgtacaagaaagttgggcaccacacaaacgcagcc;Ies2 upper,
ggggacaactttgtacaaaaaagttggcatggaggcccctgagccg; Ies2 lower,
ggggacaactttgtacaagaaagttgggtacgtagccaaaagggg.

cDNAs carried by pENTRY vector were transferred into 4 pBABE-based destination
vectors (pB-CMV-DEST-VN-neo, pB-CMV-VN-DEST-neo, pB-CMV-DEST-YFPC122

puro and pB-CMV-YFPC-DEST-puro, respectively) in LR reaction. Expression
plasmids were transfected into HEK 293 or HEK293T cells with Fugen6.

2.0 Immunobloting and Green Fluorescent Signal Detection

Proteins were separated by 8% SDS/PAGE gel. C- and N-terminal GFP fragment
tagged INO80 subunits were detected by incubating with polyclonal anti-GFP
antibody (SC-9996) overnight at 4oC. For green fluorescent signal detection, cells
transiently transfected with expression plasmids were cultured on cover slips until
reaching confluence. Slips were then carefully washed with PBS, incubated with 4%
paraformaldehyde for 10 minutes and fixed with 0.5% triton solution for 15 minutes
in R.T. before mounted on glass slides and visualized under fluorescence
microscope (Leica DM4000B).
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Results

1.0 Constructions and expressions of YFP-tagged INO80 subunits

In order to explore molecular structure of INO80 complex, I performed BiFC assay to
study protein-protein interactions within this complex. 7 core subunits of this complex
were selected for this assay, including Arp4, Arp5, Arp8, Rvb1, Rvb2, Ies2 and Ies6.
All of them are orthologs of yeast INO80 complex core components. Specially, Arp5
and Arp8 are exclusively presented in INO80 complex.

cDNA of 7 INO80 subunits were each seperately cloned into 4 distinct destination
vectors, which fuse C- or N-terminal venus YFP fragment at either end of targeted
protein, respectively. These expression constructs were next transfected into
HEK293 cells. Twenty hours after tranfection, cells were collected for western blots
against a polyclonal anti-GFP antibody, which is capable of detecting YFP. As
shown in Figure 3, expressions of 4 versions of fusion proteins from 7 subunits were
detected.
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2.0 Fluorescence microscopy

To detect all potential protein-protein interactions among the 7 targeted subunits, I
cross-tested all possible combinations of protein pairs. Expression plasmid with
fused N-terminal YFP fragment was co-transfected with each of all expression
plasmids that fused with C-terminal YFP fragment, respectively. TPP1 and TIN2
fusion proteins were used as positive controls. Fluorescent signals were visualized
under UV microscopy. In summary, several protein-protein interactions were
detected, although the fluorescent signal strength varies (Figure 4. & Table 4.).
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Discussion

The architectures of both yeast and human INO80 complex remain poorly
understood. Data from tandem affinity purification assays (Molecular Interactions
Database, http://mint.bio.uniroma2.it/mint/Welcome.do) suggests that yeast Arp4,
Arp5, Arp8, Rvb1, Rvb2, Ies2 and Ies6 have direct interactions with each other.
However, affinity purifications may not represent real situations in cellular
environment. Furthermore, although highly conserved, human INO80 complex may
not share the same structural features with that of the lower eukaryotes.

From several duplicated experiments, I was able to detect interactions between
Rvb1-Rvb2, Ies6-Rvb2, Arp8-Rvb2 and Arp5-Ies6. As expected, among all
detectable interactions, the Rvb1-Rvb2 pair exhibits the highest signal strength. This
phenomenon may simply due to the relatively higher concentration of Rvb1-Rvb2
subunit, which has a 6-fold stoichiometry against Ino80 in IP assay and also
presents in other complex (137). Surprisingly, all interactions between INO80
components were detected both in cytoplasm and nucleus. It indicates that the
INO80 complex may also present in cytoplasm. However, the immunostaining of
Ino80 protein from Dr. Shen Xuetong and our labs suggested nuclear localization of
this protein (131, Data not shown). Moreover, although the cytoplasmic localization
of Rvb1/Rvb2 has been reported previously (145, 146), the function of cytoplasmic
Rvbs remains unknown.
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At the same time, I was unable to detect fluorescent signals among 3 Actin-related
proteins, namely, Arp4, Arp5 and Arp8. It is possible that the impacted INO80
complex structure prevents reassembling of YPF fragments. It is also possible,
however, that Arp proteins may not interact with each other directly. Previous studies
have revealed that Ino80 contains docking sites for Actin, Arps, Rvbs and Ies
subunits. Thus, Arp4, Arp5 and Arp8 proteins may interact directly with Ino80 and
Actin. To further dissect structure of INO80 complex and reveal its localization in
vivo, it is necessary to develop BiFC constructs of Ino80 and Actin.

Another potential factor affecting the BiFC assay is its sensivity of detection. The
interactions listed in Table 4 are detected by eye under microscope, which is limited
by the sensitivity of human vision. It is possible that there are weak interactions or
interactions that do not allow an perfect structural reconstitution of the YFG protein.
In such a case, certain protein protein interactions may be undetectable by visual
analysis. It may require flow cytomentry to carry out further and more quantitative
analysis.
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